Meetings and materials

The P&T Committee / DUR Board meet at least quarterly. All meetings are open to the public.

Meetings and materials: Pharmacy and Therapeutic (P&T) Committee/Drug Utilization Review (DUR) Board

Upcoming meetings

August 16, 2017
October 18, 2017
December 20, 2017

Materials

Drug class reports will be taken down 30 days after the meeting.

Date	General Documents	P&T Documents	P&T Motions	DUR Documents
June 21, 2017	Agenda	Antiemetic Anticoagulant ADHD MS Drugs	Antiemetics motion Anticoagulant motion ADHD motion MS Drugs motion	Drug class policy Bisphosphonates Warnings on Codeine & Tramadol pediatric use
April 19, 2017	Agenda P&T Committee overview Transcript		Hormone Replacement Therapy Insomnia Statins Antidepressants PCSK9 Inhibitors	Emflaza report Drug utilization & clinical policy Emflaza (deflazacort) clinical policy Exondys 51 summary review Exondys 51 policy CDER full review of Exondys 51
February 22, 2017 Held at HCA	Agenda Transcript			Exondys 51 policy Exondys 51 monograph Proton Pump Inhibitor policy Spinraza policy
January 26, 2017 Held at HCA	Agenda Transcript			Opioid policy for children

Meeting details

All P&T Committee/DUR Board meetings are open to the public.
Sign up at the meeting to testify on a drug class. Stakeholder sign-up sheets are located in the lobby.
Stakeholders will be allowed 3 minutes for comments.
If you would like to give testimony, but cannot attend a meeting, please email a letter to Leta Evaskus at least two weeks before the meeting. She will put your testimony in the P&T Committee binders.
Committee discussion and motions follow stakeholder comments.
Meetings are sponsored by the Health Care Authority and meet requirements of the Americans with Disabilities Act. Please call our ADA Coordinator at 360-725-9976 to make a request for special accommodations. TTY users may call this number through the Washington Relay Service by dialing 711.

Medicaid supplemental rebate requests

Electronic submission of drug manufacturer rebate offers must be sent to contracts@hca.wa.gov and received one week prior to the P&T meeting.

Faxes or written submissions will not be accepted. No bids will be entertained until the drug class is evaluated per the P&T Committee schedule. If you have questions about specific drugs that are included in these drug class reviews, please email Julie Hartford or call 360-725-1846.

Request archived materials

Leta Evaskus
Email: leta.evaskus@hca.wa.gov
Phone: 206-521-2029

Stakeholder list

If you would like to receive P&T meeting agendas, Medicaid supplemental rebate requests, and drug class updates, please send your name and email address to:

Leta Evaskus
Email: leta.evaskus@hca.wa.gov